Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 94Prostatic Neoplasms, Castration-Resistant 10Neoplasm Metastasis 8Breast Neoplasms 8Neoplasms 7Triple Negative Breast Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Bulbo-Spinal Atrophy, X-Linked 3Adenocarcinoma 3mCRPC 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostate Adenocarcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Bites and Stings 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1

Interventions

sipuleucel-T 2enzalutamide 2gallium 68 PSMA-11 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × enzalutamide × 1 year × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

British Columbia Cancer Agency

Phase 2 Active not recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡